|
Originally published In Press as doi:10.1074/jbc.M103304200 on June 18, 2001
J. Biol. Chem., Vol. 276, Issue 35, 33121-33128, August 31, 2001
Characterization of Selected Strains of
Pneumococcal Surface Protein A*
Mark J.
Jedrzejas §,
Ejvis
Lamani , and
Robert S.
Becker¶
From the Department of Microbiology, University of
Alabama at Birmingham, Birmingham, Alabama 35294 and ¶ Aventis
Pasteur, Swiftwater, Pennsylvania 18370
Several proteins, in addition to the
polysaccharide capsule, have recently been implicated in the full
virulence of the Streptococcus pneumoniae bacterial
pathogen. One of these novel virulence factors of S. pneumoniae is pneumococcal surface protein A (PspA). The N-terminal, cell surface exposed, and functional part of PspA is
essential for full pneumococcal virulence, as evidenced by the fact
that antibodies raised against this part of the protein are protective
against pneumococcal infections. PspA has recently been implicated in
anti-complementary function as it reduces complement-mediated clearance
and phagocytosis of pneumococci. Several recombinant N-terminal
fragments of PspA from different strains of pneumococci, Rx1, BG9739,
BG6380, EF3296, and EF5668, were analyzed using circular dichroism,
analytical ultracentrifugation sedimentation velocity and equilibrium
methods, and sequence homology. Uniformly, all strains of PspA
molecules studied have a high -helical secondary structure content
and they adopt predominantly a coiled-coil structure with an elongated,
likely rod-like shape. No -sheet structures were detected for any of
the PspA molecules analyzed. All PspAs were found to be monomeric in
solution with the exception of the BG9739 strain which had the
propensity to partially aggregate but only into a tetrameric form.
These structural properties were correlated with the functional,
anti-complementary properties of PspA molecules based on the polar
distribution of highly charged termini of its coiled-coil domain. The
recombinant Rx1 PspA is currently under consideration for pneumococcal
vaccine development.
*
This work was supported by a contract from Aventis Pasteur
(to M. J. J.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Children's Hospital
Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland,
CA 94609-1673. Tel.: 510-450-7932; Fax: 510-450-7910; E-mail:
mjedrzejas@chori.org.
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. M. A. Graham and J. C. Paton
Differential Role of CbpA and PspA in Modulation of In Vitro CXC Chemokine Responses of Respiratory Epithelial Cells to Infection with Streptococcus pneumoniae
Infect. Immun.,
December 1, 2006;
74(12):
6739 - 6749.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Segal and A. J. Pollard
Vaccines against bacterial meningitis
Br. Med. Bull.,
March 31, 2005;
72(1):
65 - 81.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Ren, A. J. Szalai, O. Thomas, S. K. Hollingshead, and D. E. Briles
Both Family 1 and Family 2 PspA Proteins Can Inhibit Complement Deposition and Confer Virulence to a Capsular Serotype 3 Strain of Streptococcus pneumoniae
Infect. Immun.,
January 1, 2003;
71(1):
75 - 85.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|